Document is current
Any future updates will be listed below
-
Authors
Li, Yumin
Wang, Li
Cheng, Huanyi
Chi, Xiumei
Huang, Qingrui
Lv, Pinxin
Zhang, Wenyi
Niu, Junqi
Wen, Xiaoyu
Liu, Zhenning
-
Funding
Funding for this research was provided by:
National Key Research and Development Program of China (2017ZX106080, 2022YFE0138500, 2017ZX106080, 2017ZX106080, 2017ZX106080, 2017ZX106080)
- License Information
-
More Information
Article History
Received: 13 May 2024
Accepted: 9 October 2024
First Online: 12 October 2024
Declarations
:
: Wenyi Zhang is a founder of Beijing Abace Biotechnology. Ruiqing Huang is an employee of Beijing Abace Biotechnology. Huanyi Cheng was an employee of Beijing Abace Biotechnology. Other authors don’t have any conflict of interest. Jilin University and Abace Biotechnology jointly own the Chinese patents for the ELISA-kit developed in this work. Abace Biotechnology holds the approval from the Food and Drug Administration of China for the ELISA-kit developed in this work.
